Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: Intraindividual comparison with double-dose gadopentetate dimeglumine

American Journal of Neuroradiology

Volumn 31, Issue 6, 2010, Pages 1055-1058

  Kim, E S ^a   Chang, J H ^a   Choi, H S ^a   Kim, J ^a   Lee, S K ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE MEGLUMINE; GADOVIST 1.0; UNCLASSIFIED DRUG; CONTRAST MEDIUM; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; KIDNEY CARCINOMA; MALE; MEDICAL RECORD; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RADIOLOGIST; SEX RATIO; BRAIN TUMOR; COMPARATIVE STUDY; DIAGNOSTIC USE; KIDNEY TUMOR; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SECONDARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953509943     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A2010     Document Type: Article

References (29)

1. Chang SD, Lee E, Sakamoto GT, et al. Stereotactic radiosurgery in patients with multiple brain metastases. Neurosurg Focus 2000;9:e3
2. Fuentes S, Delsanti C, Metellus P, et al. Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 2006;58:37- 42, discussion 37-42
3. Yuh WT, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995;16:373-80
4. Sze G, Johnson C, Kawamura Y, et al. Comparison of single- and triple-dose contrast material in theMRscreening of brain metastases. AJNR Am J Neuroradiol 1998;19:821-28
5. Yuh WT, Engelken JD, Muhonen MG, et al. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 1992;13:335-45
6. Fellner F, Lungenschmid K, Fellner C, et al. Experiences with gadodiamide, a non-ionic contrast agent, in MRI of brain metastases. Rontgenpraxis 1998;51:203-11
7. Akeson P, Larsson EM, Kristoffersen DT, et al. Brain metastases: comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995;36:300-06
8. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557-66
9. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684-91
10. Tatsuno S, Hata Y, Tada S. Double-dose Gd-DTPA: detectability of intraparenchymal brain metastasis [in Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 1996;56:855-59
11. van der Molen AJ, Bellin MF. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy. Eur J Radiol 2008;66:168-74
12. Vogl TJ, Friebe CE, Balzer T, et al. Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol: intraindividual evaluation of a phase II high dose study [in German]. Radiologe 1995;35:508-16
13. Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994;29:709-15
14. Balzer JO, Loewe C, Davis K, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol 2003;13:2067-74
15. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1-10
16. Tombach B, Heindel W. Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550-56
17. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol 2009;44:251-56
18. Giesel FL, Mehndiratta A, Risse F, et al. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla. Acta Radiol 2009:50:521-30
19. Lemke AJ, Sander B, Balzer T, et al. Safety and use of gadobutrol in patients with brain tumors (phase III trial) [in German]. Rofo 1997;167:591-98
20. Anzalone N, Gerevini S, Scotti R, et al. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009:50:933-40
21. Thilmann O, Larsson EM, Bjorkman-Burtscher IM, et al. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 2005;22:597-604
22. Benner T, Reimer P, Erb G, et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000;12:371-80
23. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-28
24. Le Duc G, Corde S, Charvet AM, et al. In vivo measurement of gadolinium concentration in a rat glioma model by monochromatic quantitative computed tomography: comparison between gadopentetate dimeglumine and gadobutrol. Invest Radiol 2004;39:385-93
25. Barker FG 2nd. Surgical and radiosurgical management of brain metastases. Surg Clin North Am 2005;85:329-45
26. Essig M, Lodemann KP, Le-Huu M, et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 2006;41:256-63
27. Gasperini C, Paolillo A, Rovaris M, et al.Acomparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761-63
28. Goyen M, Herborn CU, Vogt FM, et al. Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging 2003;17:565-71
29. Ewing JR, Brown SL, Nagaraja TN, et al. MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging 2008;27:1430-38